Tactile Systems Technology Reports Q3 2026 Revenue Growth Driven by Lymphedema Segment
Tactile Systems Technology (TCMD) reported third-quarter revenue of $91.9 million, a 7% increase year-over-year. The growth was primarily driven by the core lymphedema product line, which saw revenue rise 13% to $81.8 million as Medicare prior authorization requirements stabilized and commercial payer access expanded. While the lymphedema segment performed strongly, airway clearance revenue declined by 25.1% due to distributor inventory transitions related to the next-generation AffloVest product. Despite this, the company raised its full-year adjusted EBITDA guidance to a range of $50 million to $52 million and maintained a strong gross margin profile, marking 12 consecutive quarters of improvement.
Topics: Airway Clearance Revenue Decline EBITDA Guidance Lymphedema Product Line Revenue Growth